Greenwood Capital Associates LLC Sells 2,059 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Greenwood Capital Associates LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,465 shares of the pharmaceutical company’s stock after selling 2,059 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Vertex Pharmaceuticals were worth $7,436,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. E. Ohman J or Asset Management AB grew its stake in shares of Vertex Pharmaceuticals by 13.9% in the fourth quarter. E. Ohman J or Asset Management AB now owns 11,740 shares of the pharmaceutical company’s stock valued at $4,728,000 after buying an additional 1,430 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $30,000. Trust Point Inc. grew its position in shares of Vertex Pharmaceuticals by 5.3% in the 4th quarter. Trust Point Inc. now owns 1,175 shares of the pharmaceutical company’s stock valued at $473,000 after acquiring an additional 59 shares during the period. Childress Capital Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 4.6% during the 4th quarter. Childress Capital Advisors LLC now owns 804 shares of the pharmaceutical company’s stock worth $324,000 after purchasing an additional 35 shares during the last quarter. Finally, Alliance Wealth Advisors LLC UT bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $377,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on VRTX. StockNews.com cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. Piper Sandler decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday. BMO Capital Markets decreased their target price on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research report on Friday, December 20th. Finally, Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $502.58.

Vertex Pharmaceuticals Trading Down 0.1 %

Shares of VRTX stock opened at $469.79 on Tuesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The stock’s fifty day simple moving average is $434.55 and its 200 day simple moving average is $462.75. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $120.99 billion, a P/E ratio of -235.90, a P/E/G ratio of 2.39 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same period in the prior year, the business posted $3.67 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.